LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2024 financial and operational ...

Explore CAR-T responses and the challenges of durability in cancer treatment with innovative NKTR-255 interleukin-15 therapy.

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

The two companies have been working together since 2017, with Takeda pledging $100 million to help GammaDelta advance its cell therapy platform as part of a "build-to-buy" arrangement. The ...

Takeda has chalked up another milestone for its Alofisel cell therapy for a complication of Crohn's disease, becoming the first allogeneic stem cell therapy to be approved in Japan.

Takeda and Protagonist Therapeutics have reported positive topline outcomes from their Phase III VERIFY trial of rusfertide ...

Allogene Therapeutics recently released exciting results from the Phase 1 ALPHA/ALPHA2 trials of the Allogeneic CAR T 'Cemacabtagene Ansegedleucel/ALLO-501' in Relapsed/Refractory Large B-Cell ...

Eligible patients must have tried at least two prior lines of systemic therapy and be ineligible for an autologous hematopoietic stem cell transplant ... Seagen in 2023. Takeda holds rights ...

Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab ... haematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy. LBCL is a form of non-Hodgkin lymphoma ...